Cullinan Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Major milestones are expected in 2026 for two T-cell engager programs targeting autoimmune diseases and AML, with key data readouts and regulatory progress anticipated throughout the year. Enhanced trial enrollment, strong early efficacy, and a robust cash position support continued advancement.
-
Key milestones are expected in 2026, with pivotal data from CLN-978 in autoimmune diseases and CLN-049 in AML anticipated throughout 2024. Both programs target significant unmet needs, with a focus on safety, efficacy, and efficient development paths.
-
Multiple clinical catalysts are expected in 2026, including key data for CLN-978 in autoimmune diseases and CLN-049 in AML, with expansion into pivotal studies. Zipalertinib is advancing toward NDA submission and frontline study completion, supported by a strong financial position.
-
Multiple portfolio catalysts are expected in 2026, with key data readouts for T cell engagers in autoimmune diseases and AML. Strong clinical progress, robust financial runway, and strategic partnerships position the company for significant growth and value creation.
Fiscal Year 2025
-
CLN-049, a FLT3-directed T-cell engager, shows robust efficacy and durable responses in relapsed/refractory AML, including TP53-mutated cases, with a favorable safety profile. Its broad applicability and regulatory progress position it for significant commercial and clinical impact.
-
Multiple pipeline catalysts are expected, with a focus on T-cell engagers for cancer and autoimmune diseases. CLN-049 shows promising response rates in AML, while CLN-978 is positioned to pioneer CD19 T-cell engager use in autoimmune indications, with strong financial runway.
-
Multiple clinical programs are advancing, with a focus on T-cell engagers for autoimmune and oncology indications. Key data readouts are expected in 2026, and recent strategic moves, including program discontinuations and new acquisitions, have strengthened the pipeline and extended financial runway to 2029.
-
The company is advancing a portfolio of oncology and autoimmune programs, with lead bispecific CLN-978 in phase 1 trials for SLE, RA, and Sjogren’s. Initial data for SLE and RA are expected in the first half of 2026. Recent protocol changes aim to boost enrollment, and financial runway extends into 2028.
-
Multiple clinical catalysts are expected in 2026, with a focus on CLN-978 for autoimmune diseases and zipolirenib for oncology. Strategic partnerships, strong cash reserves, and protocol amendments are driving accelerated development and broader market reach.
-
Multiple near-term catalysts are expected as the pipeline advances, with CLN-978 leading in autoimmune indications and zipalertinib progressing toward NDA submission. Protocol amendments aim to accelerate lupus trial enrollment, and strong financials support execution into 2028.
-
Exclusive global rights to Velinotamig expand the pipeline to target both B-cell and plasma cell-driven autoimmune diseases, complementing CLN-978. The deal offers strong clinical and financial positioning, with a focus on rapid development and a cash runway into 2028.
-
Cell therapy and T-cell engagers are showing promising, durable responses in autoimmune diseases, with safety and patient selection emerging as key differentiators. Multiple modalities are expected to coexist, and regulatory progress is accelerating, with pivotal filings anticipated soon.
-
Zipalertinib demonstrated strong efficacy and tolerability in the REZILIENT1 study, including in patients with brain metastases and those heavily pretreated. Real-world cases and physician feedback highlight its potential to shift treatment preferences toward an oral, well-tolerated option. Regulatory filings and new data are expected later this year.
-
2025 is set as a pivotal year, with a robust pipeline spanning oncology and autoimmune diseases, highlighted by CLN-978's global studies and upcoming lupus data. Strong financials, strategic partnerships, and differentiated T-cell engager technology position the company for multiple near-term catalysts.
-
Multiple clinical catalysts are expected in 2024, including data from lupus and oncology studies. T cell engagers are positioned as potent, off-the-shelf alternatives to CAR-T, with favorable safety and commercial potential in large autoimmune and cancer markets.
-
Expanded into immunology in 2024, advancing CLN-978 for SLE and RA with key data expected by year-end. Oncology pipeline progresses with zipalertinib meeting its Phase 2B endpoint and NDA submission planned for late 2024.
Fiscal Year 2024
-
The company expanded into autoimmune diseases with CLN-978, now in global SLE and upcoming RA trials, while maintaining momentum in oncology with CLN-619 and zipalertinib. Strong cash reserves support a runway into 2028, with key data readouts expected in 2025.
-
Management outlined progress in autoimmune and oncology pipelines, highlighting CLN-978's global SLE and RA studies, strong rationale for CD19 targeting, and robust clinical data for CLN-619 and Zipilertinib. Cash runway extends into 2028, supporting continued development.
-
The company is advancing a diversified pipeline in oncology and autoimmune diseases, with CLN-978 leading the expansion into lupus and rheumatoid arthritis. T cell engagers are positioned as a safer, more accessible alternative to CAR-T, while oncology assets like CLN-619 and zipalertinib show promising efficacy in difficult-to-treat cancers.
-
A diversified pipeline is advancing with multiple clinical catalysts expected through 2025, including promising data for CLN-619 and zipalertinib in difficult-to-treat cancers. Recent financing secures operations into 2028, supporting ongoing expansion in oncology and immunology.